1. Peptide Agonists of Vasopressin V2 Receptor Reduce Expression of Neuroendocrine Markers and Tumor Growth in Human Lung and Prostate Tumor Cells
   Marina Pifano et al, 2017, Frontiers in Oncology CrossRef
2. New drugs are not enough‑drug repositioning in oncology: An update
   Romina Armando et al, 2020, International Journal of Oncology CrossRef
3. Building analytical models for predicting de novo malignancy in pancreas transplant patients: A machine learning approach
   Amir Zadeh et al, 2024, Expert Systems with Applications CrossRef
4. Exploiting cancer’s phenotypic guise against itself: targeting ectopically expressed peptide G-protein coupled receptors for lung cancer therapy
   Mahjabin Khan et al, 2017, Oncotarget CrossRef
5. Vasopressin and Its Analogues: From Natural Hormones to Multitasking Peptides
   Mladena Glavaš et al, 2022, International Journal of Molecular Sciences CrossRef
6. Gαs and Gαq/11 protein coupling bias of two AVPR2 mutants (R68W and V162A) that cause nephrogenic diabetes insipidus
   Beril Erdem Tuncdemir, 2022, Journal of Receptors and Signal Transduction CrossRef
7. AVPR2 is a potential prognostic biomarker and correlated with immune infiltration in head and neck squamous cell carcinoma
   Linwei Mao et al, 2023, BMC Medical Genomics CrossRef
8. Repurposing of Chronically Used Drugs in Cancer Therapy: A Chance to Grasp
   Mohamad Ali Hijazi et al, 2023, Cancers CrossRef
9. Addition of vasopressin synthetic analogue [V4Q5]dDAVP to standard chemotherapy enhances tumour growth inhibition and impairs metastatic spread in aggressive breast tumour models
   Juan Garona et al, 2016, Clinical & Experimental Metastasis CrossRef
10. Commentary: Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer
    Giselle V. Ripoll et al, 2020, Frontiers in Oncology CrossRef
11. Development and therapeutic potential of vasopressin synthetic analog [V4Q5]dDAVP as a novel anticancer agent
    Juan Garona et al, 2020, Vasopressin CrossRef
12. Yohimbine as a Starting Point to Access Diverse Natural Product-Like Agents with Re-programmed Activities against Cancer-Relevant GPCR Targets
    Nicholas G. Paciaroni et al, 2020, Bioorganic & Medicinal Chemistry CrossRef
13. Exploiting Dependence of Castration-Resistant Prostate Cancer on the Arginine Vasopressin Signaling Axis by Repurposing Vaptans
    Laine M. Heidman et al, 2022, Molecular Cancer Research CrossRef
14. Effect of Ivermectin and Atorvastatin on Nuclear Localization of Importin Alpha and Drug Target Expression Profiling in Host Cells from Nasopharyngeal Swabs of SARS-CoV-2- Positive Patients
    Valeria Inés Segatori et al, 2021, Viruses CrossRef
15. High Oxytocin Receptor Expression Linked to Increased Cell Migration and Reduced Survival in Patients with Triple-Negative Breast Cancer
    Huiping Liu et al, 2022, Biomedicines CrossRef
16. Search of vasopressin analogs with antiproliferative activity on small-cell lung cancer: drug design based on two different approaches
    Marina Pifano et al, 2018, Future Medicinal Chemistry CrossRef
17. Preclinical Efficacy of [V4 Q5 ]dDAVP, a Second Generation Vasopressin Analog, on Metastatic Spread and Tumor-Associated Angiogenesis in Colorectal Cancer
    Juan Garona et al, 2019, Cancer Research and Treatment CrossRef
18. Noncanonical effects of vasopressin in angiogenesis
    I. I. Khegay, 2019, Vavilov Journal of Genetics and Breeding CrossRef
19. Targeting the vasopressin type-2 receptor for renal cell carcinoma therapy
    Sonali Sinha et al, 2020, Oncogene CrossRef
20. β-Arrestin inhibition induces autophagy, apoptosis, G0/G1 cell cycle arrest in agonist-activated V2R receptor in breast cancer cells
    Thoria Donia et al, 2021, Medical Oncology CrossRef
21. Propranolol blocks osteosarcoma cell cycle progression, inhibits angiogenesis and slows xenograft growth in combination with cisplatin-based chemotherapy
    Luisina M. Solernó et al, 2022, Scientific Reports CrossRef
22. Repurposing of Guanabenz acetate by encapsulation into long-circulating nanopolymersomes for treatment of triple-negative breast cancer
    Yusuf A. Haggag et al, 2021, International Journal of Pharmaceutics CrossRef
23. A phase II dose-escalation trial of perioperative desmopressin (1-desamino-8-d-arginine vasopressin) in breast cancer patients
    Ruth S Weinberg et al, 2015, SpringerPlus CrossRef
24. In vitroandin vivoevaluation of desmopressin-loaded poly(D,L-lactic-co-glycolic acid) nanoparticles for its potential use in cancer treatment
    Merari T Chevalier et al, 2018, Nanomedicine CrossRef